Monthly Archives: March 2022

Abbott’s FreeStyle Libre is First and Only CGM System to Gain Expanded Reimbursement in Japan to Include All People with Diabetes Who Use Insulin – PR…

Posted: March 25, 2022 at 2:29 am

ABBOTT PARK, Ill., March 24, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the expansion of reimbursement coverage for its FreeStyle Libre system to include all people with diabetes who use insulin at least once a day.

The expanded coverage will enable more people with diabetes to access the glucose data needed to manage their condition without the routine fingersticks1 associated with traditional blood glucose monitoring.

"The best healthcare solution is the one that helps the most people, which is why we designed our FreeStyle Libre system with access and affordability in mind from the very beginning," said Jared Watkin, senior vice president of Abbott's diabetes care business. "FreeStyle Libre systems provide a complete and comprehensive glucose picture without the need for routine fingersticks. The technology helps enable behavior change, which ultimately helps people live better, fuller lives."

The reimbursement expansion, which will go into effect April 1, 2022, was granted based on FreeStyle Libre's overall value proposition, which includes ease of use and scientific evidence that shows the clinical benefits of using the FreeStyle Libre system among all people who take self-injections of insulin.2,3,4

"With the expanded reimbursement coverage, healthcare professionals like me will be equipped with continuous glucose monitoring information and actionable insights for patients with diabetes, which has previously been available mainly to a limited population of people who require multiple daily injections of insulin. This will allow patients to have a better understanding and control of their diabetes based on glucose fluctuation through continuous monitoring," said Dr. Wataru Ogawa, professor, Division of Diabetes and Digestive and Kidney Diseases, Kobe University Graduate School of Medicine. "I am expecting this will lead to better management of my patients' overall condition, as well as reduce the future risks of diabetes-related complications."

About AbbottAbbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 113,000 colleagues serve people in more than 160 countries.

Connect with us at http://www.abbott.com, on LinkedIn at http://www.linkedin.com/company/abbott-/, on Facebook at http://www.facebook.com/Abbott and on Twitter @AbbottNews.

1 A fingerstick test using a blood glucose meter is required when there are questions on the accuracy of the interstitial fluid glucose levels or impending hypoglycaemia or hypoglycaemia as reported by the system or when symptoms do not match the system readings.2 Miller, Brandner et al. HbA1c Reduction After Initiation of the FreeStyle Libre System in Type 2 Diabetes Patients on Long-Acting Insulin or Non-Insulin Therapy.3 Miller et al. FreeStyle Libre System Use Associated with Reduction in Acute Diabetes Events and All-Cause Hospitalizations in Patients with Type 2 Diabetes Without Bolus Insulin.4 Wright et al. HbA1c Reduction Associated with a FreeStyle Libre System in People with Type 2 Diabetes Not on Bolus Insulin Therapy.

SOURCE Abbott

See more here:
Abbott's FreeStyle Libre is First and Only CGM System to Gain Expanded Reimbursement in Japan to Include All People with Diabetes Who Use Insulin - PR...

Posted in Diabetes | Comments Off on Abbott’s FreeStyle Libre is First and Only CGM System to Gain Expanded Reimbursement in Japan to Include All People with Diabetes Who Use Insulin – PR…

Could a 100-year-old vaccine treat Type 1 diabetes? MGH researchers are working to find out. – The Boston Globe

Posted: March 25, 2022 at 2:29 am

Studies have tied the vaccine to lower rates of childhood mortality and stronger immunity against a host of infectious diseases. There are also signs the vaccine can calm the immune system, benefiting people with allergies and autoimmune diseases.

Around the world, trials are underway to research BCG in multiple sclerosis, Alzheimers, and COVID-19.

Faustmans lab, in partnership with NYU Langone Health, is recruiting 150 adolescents with Type 1 diabetes for pediatric clinical trials of the shots. All participants must be between the ages of 12 and 17 and have had the disease for at least two years.

The research builds on studies Faustman has conducted over the last decade.

A small phase 1 clinical trial, published in 2012, showed BCG prompted higher levels of insulin production than in placebo-treated subjects. In a long-term follow of the trial, published in 2018, Faustmans lab found that adult patients with diabetes treated with the vaccine experienced 10 to 18 percent reductions in blood sugar levels and were able to use less insulin. Diabetic patients in the same trial who were treated with a placebo showed almost no improvement.

Research has found that reducing levels of hemoglobin A1c, a measure of blood glucose, by even 10 percent can lower the risk of lifelong complications from diabetes.

A phase two clinical trial, begun in 2015 with 150 patients, is ongoing, with results expected in a year and a half.

Faustman said BCG appears to help patients with Type 1 diabetes by altering their immune system.

In individuals with the disease, the body produces abnormal white blood cells that attack insulin-secreting cells in the pancreas.

Faustmans research suggests BCG can turn on good white blood cells and destroy bad white blood cells prone to attacking the pancreas. Further, the vaccine fixes defects in the white blood cells of diabetes patients, allowing the cells to process sugar and draw more of it out of the blood, Faustman said.

Key to BCGs potency, Faustman and others believe, is the fact that it is a live vaccine. It uses a weakened form of the bacteria that cause tuberculosis, reintroducing a key microbe to the body that humans stopped interacting with as society became more hygienic.

Its amazing to think about how a bug could, over a period after vaccination, reprogram cells in permanent ways that result in immune responses, Faustman said.

Faustmans research, which is still in early stages, has met with controversy.

After she published her phase 1 research in 2018, JDRF, formerly known as the Juvenile Diabetes Research Foundation, and the American Diabetes Association issued a joint statement saying it wasnt clear that lowered insulin levels were a direct result of the vaccine, as levels tend to change over time, and said the small number of participants wasnt robust enough to be generalized to the larger population.

In a statement to the Globe, JDRF said its position on Faustmans research had not changed.

The ADA did not respond to a request for comment.

Other researchers also have been skeptical.

Its not something being pursued or taken seriously by the rest of the field, said Stephan Kissler, a Type 1 diabetes researcher at Joslin Diabetes Center.

Other more mainstream diabetes experts are pursuing avenues such as immunosuppression and creating insulin-producing cells out of stem cells that can be transplanted back into patients bodies. Kissler works to genetically alter transplanted cells so they dont require recipients to take immunosuppressants.

We want to change their disease, said Kissler.

Yet Faustman sees her work as a stepping stone to do just that. The pediatric clinical trial will focus on children who are at an early enough stage in the disease to still have some pancreas function.

When we go into older people, they have no pancreas reserve, Faustman said. So were only testing in them what does BCG do to become a better regulator of glucose metabolism. Now, when we go into kids, it tests the ability of BCG to possibly preserve the pancreas as well as change these sugar defects.

Its an exciting population to study. You get to see if you stop the immune response, can the pancreas recover or become more stable as well as getting white blood cells to behave.

Dr. Joseph Bellanti, a professor emeritus of pediatrics and microbiology-immunology at Georgetown University Medical Center, said the work is innovative and the clinical trials conducted so far were encouraging.

People are entitled to their opinions. My opinion is they are on to something. And its worthy of being pursued, he said.

Ultimately, Faustman hopes to begin another set of clinical trials by the end of this year in children who have just been diagnosed with diabetes, which could change the course of the disease even earlier.

She is undeterred by the skepticism, saying the number and scope of clinical trials involving BCG speaks to its promise.

When you see a global momentum to study these off-target effects in humans, you start to see the validity of reintroducing this microbe, Faustman said.

Jessica Bartlett can be reached at jessica.bartlett@globe.com. Follow her on Twitter @ByJessBartlett.

Read this article:
Could a 100-year-old vaccine treat Type 1 diabetes? MGH researchers are working to find out. - The Boston Globe

Posted in Diabetes | Comments Off on Could a 100-year-old vaccine treat Type 1 diabetes? MGH researchers are working to find out. – The Boston Globe

Sugar-Free Drinks Linked to Weight Loss and Lower Diabetes Risk – Everyday Health

Posted: March 25, 2022 at 2:29 am

If you drink diet soda or add a little Equal to your coffee as a way to cut down on added sugar, heres some good news: Drinking no- or low-calorie beverages instead of sugar-sweetened drinks was linked with small decreases in weight, BMI, and diabetes risk in a new meta-analysis published on March 14 in JAMA Network Open.

Participants who consumed low and no-calorie beverages saw positive effects similar to those researchers would expect from water, says Tauseef Ahmad Khan, MBBS, PhD, a researcher at the University of Toronto department of nutritional sciences and a coauthor of the study.

Ideally, you would replace sugary beverages with water as much as possible, but our findings show that people have another choice a low-calorie or no-calorie beverage is a good option as well, says Dr. Khan.

The average American consumes 22 teaspoons (tsp) of added sugar a day, which translates into about 350 calories, according to the Harvard T.H. Chan School of Public Health. One tsp of sugar is equal to 4 grams (g) of sugar.

The American Heart Association (AHA) recommends that people cut back on added sugar to help reduce the risk of heart disease and obesity by limiting daily intake to about 6 tsp or 24 g of sugar for women and 9 tsp or 36 g of sugar for men.

Heres a sampling of how much sugar is found in a 12 ounce (oz) serving of some popular drinks, according to the Harvard T.H. Chan School of Public Health:

The overall effects of nonnutritive sweeteners (NNSs) the scientific name for sweeteners such as aspartame, stevia, and sucralose on metabolism and weight is unclear. Although artificially sweetened beverages may help save on calories, experts have been divided on whether they may cause unintended negative effects on metabolism and even impede weight loss efforts.

A study published in Naturefound that artificial sweeteners induced glucose intolerance and weight gain in mice. Glucose intolerance increases the risk of diabetes and cardiovascular disease, according to StatPearls.

Its also been found that drinks containing sucralose (which goes by the brand name Splenda) may increase food cravings and appetite in women and people with obesity, according to a study published in JAMA Network OpeninSeptember 2021.

Some observational studies have suggested that the use of NNSs, such as sucralose and aspartame, is associated with higher body weight and type 2 diabetes, according to a review published in Obesityin March 2018.Because those studies were not interventions researchers simply observed and compared what people were already doing, its unclear whether the alternative sweeteners were actually contributing to those issues or if people were drinking low calorie drinks in response to already having overweight or diabetes.

But the same review found that when researchers looked at prospective randomized controlled trials, NNSs actually helped with weight loss, especially when used with behavioral weight loss support.

Because health experts and organizations have been instructing people to reduce their consumption of sugary drinks, we wanted to find out if people who want to switch from sugar-sweetened beverages to water or low-calorie sweetened beverages would see any benefit, explains Khan.

Researchers analyzed 17 randomized trials that investigated how drinking water, no or low-calorie drinks, or sugar-sweetened drinks impacted body weight, other measures of fat, and cardiometabolic risk. The trials included a total of 1,733 adults with overweight or obesity who were at risk for or already had diabetes. Participants were 77.4 percent women and 22.6 percent men, with an average age of 33.

The included studies lasted anywhere from just three weeks to a year, with the average trial lasting 12 weeks.

The effects were modest, but overall beneficial, according to the findings. On average, switching to the sugar-free drinks reduced body weight by about 2 pounds (lb), lowered BMI by .2 points, and reduced body fat by about half a percent.

Water or alternatively sweetened drinks were also linked to a reduction in intrahepatocellular lipid (IHL). IHL accumulation (nonalcoholic fatty liver disease) is associated with cardiovascular disease and type 2 diabetes, according to the National Institute of Diabetes and Digestive and Kidney Diseases.

Our analysis is unique in that in addition to comparing sugary drinks to alternatively sweetened drinks, we also included water in our study. We found the benefits of switching from sugary drinks to either no- or low-calorie beverages or water were very similar, says Khan.

There are a few limitations to the findings, he says. Our analysis grouped all no- and low-calorie sweetened drinks together it didnt separate and compare according to what was used to sweeten them, says Khan.

For example, if you are wondering about the difference between drinking Diet Coke (which uses aspartame as its sweetening agent) or Coke Zero (which uses both aspartame and acesulfame potassium), these findings wont help you figure that out, he says.

Any questions about long-term impact positive or negative of drinking no- or low-calorie drinks are still unanswered, says Khan. The longest study included in our analysis lasted one year, and so further study is needed to look at what the health impacts might be 5 or 10 years down the line, he says.

Original post:
Sugar-Free Drinks Linked to Weight Loss and Lower Diabetes Risk - Everyday Health

Posted in Diabetes | Comments Off on Sugar-Free Drinks Linked to Weight Loss and Lower Diabetes Risk – Everyday Health

Eat carbs in the morning to live longer with diabetes, study says – Insider

Posted: March 25, 2022 at 2:29 am

If you have diabetes , eating more carbs in the morning and leafy greens at night may help you live longer, according to new researchpublished March 15 in The Journal of Clinical Endocrinology and Metabolism.

Researchers from Harbin Medical University in China looked at data from 4642 Americans with diabetes over 11 years of follow up as part of the NHANES study. They compared eating habits, based on 24-hour food questionnaires, with levels of cardiovascular disease and all-cause mortality over time.

The researchers found participants who ate carbs-rich veggies like potatoes earlier in the day were less likely to die of heart disease . The same was true of participants who ate whole grains in the afternoon, and those who ate dark, leafy vegetables at night.

In contrast, eating a lot of processed meat in the evening was linked to higher risk of dying of heart disease, according to data.

The researchers' data modeling suggested that switching even a tenth of a serving to a more ideal meal time was linked to a significant risk reduction for instance, swapping a portion of potatoes from dinner to breakfast, or whole grains from breakfast to lunch.

The results suggest nutrient timing could help people with diabetes match their meals to natural biological rhythms of insulin sensitivity to improve their longevity.

"Nutritional guidelines and intervention strategies for diabetes should integrate the optimal consumption times for foods in the future," Dr.Qingrao Son, co-author of the study and researcher at Harbin Medical University, said in a press release.

The study is supported by previous research from the same authors which found people with diabetes had better survival rates if they regularly ate a bigger breakfast than dinner.

Meal timing may matter whether or not you have diabetes, too. Skipping breakfast isn't always deal breaker for a healthy diet, but it is associated with more variable blood sugar levels and possibly dips in performance at work, school, and the gym, experts previously told Insider.

Eating more early in the day and less at night is also linked to a healthy weight, possibly because it helps you avoid late-night snack attacks tending toward calorie-dense, less nutritious foods like chips, alcohol, and the like.

While more research is needed on meal timing,what you eat overall may still be more important than when you eat, studies suggest.

Visit link:
Eat carbs in the morning to live longer with diabetes, study says - Insider

Posted in Diabetes | Comments Off on Eat carbs in the morning to live longer with diabetes, study says – Insider

T-cell Transfer Therapy – Immunotherapy – National Cancer …

Posted: March 25, 2022 at 2:27 am

T-cell transfer therapy can cause side effects, which people experience in different ways. The side effects you may have and how serious they are will depend on how healthy you are before treatment, your type of cancer, how advanced it is, the type of T-cell transfer therapy you are receiving, and the dose.

Doctors and nurses cannot know for sure when or if side effects will occur or how they will affect you. So, it is important to know which signs to look for and what to do if you start to have problems.

CAR T-cell therapy can cause a serious side effect known as cytokine release syndrome. This syndrome is caused when the transferred T cells, or other immune cells responding to the new T cells, release a large amount of cytokines into the blood.

Cytokines are immune substances that have many different functions in the body. A sudden increase in their levels can cause:

Most people have a mild form of cytokine release syndrome. But in some people, it may be severe or life-threatening.

Also, although CAR T cells are designed to recognize proteins that are found only on cancer cells, they can also sometimes recognize normal cells. Depending on which normal cells are recognized, this can cause a range of side effects, including organ damage.

TIL therapy can cause capillary leak syndrome. This syndrome causes fluid and proteins to leak out of tiny blood vessels and flow into surrounding tissues, resulting in dangerously low blood pressure. Capillary leak syndrome may lead to multiple organ failure and shock.

For more information about CAR T-cell therapy see CAR T-Cell Therapy: Engineering Patients' Immune Cells to Treat Their Cancers.

Access the508-compliant version of this video.

Continue reading here:
T-cell Transfer Therapy - Immunotherapy - National Cancer ...

Posted in Cell Therapy | Comments Off on T-cell Transfer Therapy – Immunotherapy – National Cancer …

CAR T-Cell Therapy – MD Anderson Cancer Center

Posted: March 25, 2022 at 2:27 am

Chimeric antigen receptor (CAR) T-cell therapy is a type of cellularimmunotherapythat changes T cells so they are able to recognize and attack cancer.

T cells are immune system cells that play several key roles in the bodys fight against disease. They help the immune system respond to disease and directly kill abnormal cells. Unfortunately, naturally occurring T cells in patients with cancer are not good at recognizing and fighting cancer cells.

CAR T-cell therapy has been extremely effective in many patients. In some cases, the treatment has eliminated all signs of cancer.

However, CAR T-cell therapy doesnt work for every patient. Some have benefited for a short time before relapsing. Doctors are studying the reasons for these different responses.

Several CAR T-cell therapies have been approved by the U.S. Food and Drug Administration (FDA). All approved products use T cells taken from the patient. Some clinical trials use T-cells taken from donors.

In both cases, the T cells are sent to a lab. There, scientists genetically modify these cells to produce a protein (called a receptor) that recognizes another protein (called an antigen) on the surface of cancer cells. This recognition allows the modified T cells to identify and attack the cancer.

The modified T cells are multiplied by the hundreds of millions and then infused into the patient to fight the disease.

There are several different types of CAR T-cell therapy produced by different drug companies. FDA-approved CAR T-cell therapies treat the following diseases:

MD Anderson is also conducting CAR T-cell therapy clinical trials for a number of other cancers. These include additional subtypes of leukemia and lymphoma; multiple myeloma; and solid tumors such as breast cancer, lung cancer, pancreatic cancer and prostate cancer. Call our CAR therapy line at 833-368-6392 for information on CAR clinical trials.

After the T cells are collected, modifying and multiplying them for infusion usually takes a few weeks. Patients may undergo other cancer treatments during this time.

When the CAR T cells are ready for use, they are sent to the hospital for infusion. Before infusion, patients are given a short course of chemotherapy. This weakens their existing immune system, giving the engineered T cells a better chance of expanding and fighting the cancer.

The infusion of the modified T cells is quick, typically lasting less than an hour.

After infusion, patients must remain near the hospital for at least four weeks. Depending on the patients type of cancer, condition and specific treatment, this time may be spent as an outpatient or a mix of both inpatient and outpatient. All patients must have a caregiver with them at all times to help care for them and monitor for side effects.

CAR T-cell therapys side effects can range from mild to serious and even life-threatening if left untreated.

The most common side effect is low counts of immune system cells. This can lead to fever and infection. This is usually a mild side effect.

Other mild side effects include nausea, vomiting and diarrhea.

CAR T-cell therapies can also have temporary but serious neurological effects, including confusion, slurred speech and seizures.

A potentially serious side effect is cytokine release syndrome (CRS). Cytokines are chemical messengers produced by T cells. They help organize the immune systems fight against disease. In CRS, too many cytokines are produced.

CRS can be mild, with symptoms such as a fever. Some cases are serious, causing dangerously low blood pressure, difficulty breathing and/or organ failure. After infusion, doctors monitor for CRS and have effective treatments for patients who develop the condition.

While these are the known side effects, CAR T-cell therapy is a new treatment and doctors are monitoring patients to uncover any long-term impacts of the treatment.

CAR T-cell therapy is the only CAR-based therapy that has been approved by the FDA. Others are in clinical trials. These include treatments that target more than one antigen on the surface of cancer cells and therapies that use natural killer (NK) cells (another type of immune system cell) instead of T cells. The treatment process and side effects for these therapies are similar to FDA-approved CAR T-cell therapies.

Call our CAR therapy line at 833-368-6392 for information on CAR clinical trials.

View post:
CAR T-Cell Therapy - MD Anderson Cancer Center

Posted in Cell Therapy | Comments Off on CAR T-Cell Therapy – MD Anderson Cancer Center

Global Cell and Gene Therapy Market – Estimated 2021, Projected 2026 and 2031 – ResearchAndMarkets.com – Business Wire

Posted: March 25, 2022 at 2:27 am

DUBLIN--(BUSINESS WIRE)--The "Cell and Gene Therapy World Market and Market Potential" report has been added to ResearchAndMarkets.com's offering.

The report examines developments in cell and gene therapy markets by condition/disorder, including principal products, trends in research and development, market breakdown of cell and gene therapies, regional market summary, and competitor summary.

Companies Mentioned

The following conditions/disorders are covered:

Dermatology, including:

Cardiovascular and Blood Disorders, including:

Oncology, including:

Ophthalmic Conditions, including:

Musculoskeletal Conditions and Disorders, including:

Other Conditions, including:

Key Topics Covered:

CHAPTER 1: EXECUTIVE SUMMARY

CHAPTER 2: INTRODUCTION TO CELL AND GENE THERAPY

CHAPTER 3: CELL AND GENE THERAPY MARKETS IN DERMATOLOGY OVERVIEW

CHAPTER 4: CELL AND GENE THERAPY MARKETS IN CARDIOVASCULAR AND BLOOD DISORDERS

CHAPTER 5: CELL AND GENE THERAPY MARKETS IN ONCOLOGY

CHAPTER 6: CELL AND GENE THERAPY MARKETS IN OPHTHALMIC CONDITIONS

CHAPTER 7: CELL AND GENE THERAPY MARKETS IN MUSCULOSKELETAL CONDITIONS AND DISORDERS

CHAPTER 9: CELL AND GENE THERAPY MARKETS IN OTHER CONDITIONS

CHAPTER 10: CELL AND GENE THERAPY MARKET REVIEW

CHAPTER 11: MARKET PARTICIPANTS

For more information about this report visit https://www.researchandmarkets.com/r/9zzs53

More here:
Global Cell and Gene Therapy Market - Estimated 2021, Projected 2026 and 2031 - ResearchAndMarkets.com - Business Wire

Posted in Cell Therapy | Comments Off on Global Cell and Gene Therapy Market – Estimated 2021, Projected 2026 and 2031 – ResearchAndMarkets.com – Business Wire

Center for Breakthrough Medicines Appoints John Lee, Ph.D. as Vice President, Head of Cell Therapy – 69News WFMZ-TV

Posted: March 25, 2022 at 2:27 am

Former GSK Executive Will Build the CDMO's Cell Therapy Infrastructure

KING OF PRUSSIA, Pa., March 23, 2022 /PRNewswire/ --The Center for Breakthrough Medicines(CBM) announced today the appointment of John Lee, Ph.D. to Vice President, Head of Cell Therapy.Dr. Lee is an accomplished CAR-T immunobiologist with over 20 years of cancer cell biology expertise spanning small and large molecules, as well as cell-based therapeutics.

"We have an opportunity to become a global leader in cell therapy," John Lee, Ph.D.

Among his accomplishments, Dr. Lee possesses more than 15 years of clinical research and cell therapy experience including positions of increasing responsibility at The Wistar Institute, Janssen Pharmaceuticals, and GlaxoSmithKline.

"I am excited to lead cell therapy at CBM and for the opportunity to cure patients," said Dr. Lee. "My goal is to build a highly functional, diverse, and agile team that embraces the challenges associated with our shared mission. By creating an infrastructure that supports both the team and our clients, we have an opportunity to become a global leader in cell therapy."

Dr. Lee previously built the Cell Therapy Platform team at Janssen Pharmaceuticals. The group led and supported end-to-end therapy discovery and development across nearly a dozen CAR-T programs, including the recently approved cilta-cel (Carvykti). During his subsequent tenure as Vice President, Head of Oncology Cell Therapy at GlaxoSmithKline, Dr. Lee's team operated within a heavily matrixed organization to support an array of activities establishing multiple preclinical assets and several clinical-stage lete-cel programs targeting the NY-ESO cancer-testis antigen.

"My collective experience leading cell therapy programs in these large organizations will help me build a fit-for-purpose infrastructure here at CBM while also creating a culture where both the team and its individual contributors can thrive," he added.

A native Pennsylvanian (from Ambler, PA), Dr. Lee is passionate about the Philadelphia life science sector. He believes CBM has the solution to attract top talent and deliver services to the capacity-starved cell and gene contract development and manufacturing organization (CDMO) market. He also feels that King of Prussia (KoP) is an ideal location for employees seeking a high quality of life. Compared to other life science clusters like those found in Cambridge, San Francisco and New Jersey, KoP offers a better quality of life with lower taxes, more affordable housing, excellent schools, and world-class restaurants.

CBM is creating the world's largest end-to-end advanced therapy CDMO. CBM will provide preclinical through commercial manufacturing services including process development, plasmid DNA, viral vectors, cell banking, cell processing, and supporting testing capabilities.

A core element of CBM's growth strategy is the construction of 700,000 square feet of GMP facility in KoP. "This capacity is part of our mission to accelerate the development and manufacturing of life-saving advanced therapies," said Joerg Ahlgrimm, Chief Executive Officer, Center for Breakthrough Medicines. "We are assembling a world-renowned executive leadership team with unique combination of experience in cell and gene therapy. John's addition to the team is another vital step in our planning for success."

To support its rapid growth, CBM is hiring positions at all levels and is actively working to develop talent among emerging professionals coming out of colleges. The company is working closely with academic institutions, as well as initiatives to retrain displaced employees. CBM is also committed to building an organization that recognizes and values diversity.

CBM is Hiring

To learn more about all CBM's open positions please visit:

https://bullseyehiringsolutions.com/companies/breakthroughmedicines

About The Center for Breakthrough Medicines

CBM is a cell and gene therapy contract development and manufacturing organization (CDMO) based in the heart of Philadelphia's Cellicon Valley. CBM offers pre-clinical through commercial manufacturing capabilities including process development, plasmid DNA, viral vector manufacturing, cell banking, cell processing, and a full suite of complimentary testing and analytical capabilities. Through a single-source, end-to-end solution, CBM accelerates time to market without compromising quality.

Media Contact:

John F. Kouten, DeFazio Communications

(o) 609-241-7352 (c) 908-227-4714

John@defaziocommunications.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/center-for-breakthrough-medicines-appoints-john-lee-phd-as-vice-president-head-of-cell-therapy-301509053.html

SOURCE Center for Breakthrough Medicines

See the rest here:
Center for Breakthrough Medicines Appoints John Lee, Ph.D. as Vice President, Head of Cell Therapy - 69News WFMZ-TV

Posted in Cell Therapy | Comments Off on Center for Breakthrough Medicines Appoints John Lee, Ph.D. as Vice President, Head of Cell Therapy – 69News WFMZ-TV

Lineage to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC on March 28, 2022 – Business Wire

Posted: March 25, 2022 at 2:27 am

CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, the Companys Chief Executive Officer, will be presenting at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest. Mr. Culley will be participating in an Ophthalmology Panel hosted by Jason McCarthy, Ph.D., Senior Managing Director, Biotechnology, on March 28th, 2022 at 10am ET / 7am PT. Mr. Culley will also provide a corporate overview which will be available to investors on demand, starting on Monday March 28th, 2022.

The live panel and on-demand presentation will be available to registered users directly through the M-Vest platform: https://m-vest.com/events/2022-virtual-growth-conference. Registration is required for conference participation. An archived webcast of the corporate presentation will also be available on the Events and Presentations page of the Lineage website. Additional videos are available on the Media page of the Lineage website.

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineages programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineages clinical programs are in markets with billion dollar opportunities and include four allogeneic (off-the-shelf) product candidates: (i) OpRegen, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, which is now being developed under a worldwide collaboration with Roche and Genentech, a member of the Roche Group; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; (iii) VAC2, a dendritic cell therapy produced from Lineages VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer and (iv) ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy. For more information, please visit http://www.lineagecell.com or follow the Company on Twitter @LineageCell.

Read the original here:
Lineage to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC on March 28, 2022 - Business Wire

Posted in Cell Therapy | Comments Off on Lineage to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC on March 28, 2022 – Business Wire

Wugen to Present at the Innate Killer Summit 2022 – Yahoo Finance

Posted: March 25, 2022 at 2:27 am

ST. LOUIS & SAN DIEGO, March 24, 2022--(BUSINESS WIRE)--Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced that management will participate in a fireside chat and presentation at the Innate Killer Summit 2022 being held in San Diego, CA from Wednesday, March 30 Friday, April 1, 2022.

The details of Wugens fireside chat and presentation are as follows:

Format: Industry Leaders Fireside ChatPresenter: Dan Kemp, Ph.D., President and Chief Executive Officer, WugenDate & Time: Thursday, March 31, 2022 at 8:15 a.m. PT

Format: Presentation titled "Characterizing an Ideal NK Cell Phenotype Leveraging Assays to Indicate Therapeutic Benefit"Presenter: Ayman Kabakibi, Ph.D., Chief Operating Officer & Executive Vice President, Research & Development, WugenDate & Time: Thursday, March 31, 2022 at 11:30 a.m. PT

About WU-NK-101

WU-NK-101 is a novel immunotherapy harnessing the power of memory natural killer (NK) cells to treat liquid and solid tumors. Memory NK cells are hyper-functional, long-lasting immune cells that exhibit enhanced anti-tumor activity. This rare cell population has a superior phenotype, proliferation capacity, and metabolic fitness that makes it better suited for cancer therapy than other NK cell therapies. Wugen is applying its proprietary MonetaTM platform to advance WU-NK-101 as a commercially scalable, off-the-shelf cell therapy for cancer. WU-NK-101 is currently in development for acute myelogenous leukemia (AML) and solid tumors.

About Wugen

Wugen, Inc., is a clinical-stage biotechnology company developing the next generation of off-the-shelf memory natural killer (NK) and CAR-T cell therapies for cancer. Wugen is leveraging its proprietary MonetaTM platform and deep genomic engineering expertise to pioneer a new class of memory NK cell therapies to treat hematological and solid tumor malignancies. For more information, please visit http://www.wugen.com.

Story continues

View source version on businesswire.com: https://www.businesswire.com/news/home/20220324005008/en/

Contacts

Investor Contact: Elsie Yau, Stern Investor Relations, Inc.212-698-8700elsie.yau@sternir.com

Go here to see the original:
Wugen to Present at the Innate Killer Summit 2022 - Yahoo Finance

Posted in Cell Therapy | Comments Off on Wugen to Present at the Innate Killer Summit 2022 – Yahoo Finance